Company / Cash & Equivalents
Immunovant, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$635.4M
FY2024
5-year range
$100.6M / $635.4M
FY2020-FY2024
Trend
+68.7%
vs FY2023
Sector context
#33 of 209
Health Care
What the data says
Immunovant, Inc.'s cash & equivalents of $635M is higher than 84% of companies in the Health Care sector (FY2024). Improved from $494M to $635M over the past 2 years.
Based on SEC 10-K filings.
$635M in FY2024 with a 5-year CAGR of +146.5%. Top quartile in the Health Care sector.
Improved from $494M to $635M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- +146.5%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 209This company $635.4M Sector average $696.0M
▼
-8.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +146.5%, indicating consistent growth.
- In FY2024, cash & equivalents increased 68.7% year-over-year.
- Ranks #33 out of 209 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $635.4M | +68.7% |
| FY2023 | $376.5M | -23.8% |
| FY2022 | $493.8M | +23.4% |
| FY2021 | $400.1M | +297.9% |
| FY2020 | $100.6M | +1339.8% |
| FY2019 | $7.0M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026